Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
|
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:ATCCode |
N06DX05
|
| gptkbp:brand |
Remternetug
|
| gptkbp:CASNumber |
1800016-26-4
|
| gptkbp:clinicalTrialPhase |
Phase 3
TRAILBLAZER-ALZ |
| gptkbp:developedBy |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:firstReported |
2018
|
| https://www.w3.org/2000/01/rdf-schema#label |
Donanemab
|
| gptkbp:intendedUse |
treatment of Alzheimer's disease
|
| gptkbp:legalStatus |
investigational
|
| gptkbp:macromoleculeType |
IgG1 monoclonal antibody
|
| gptkbp:mechanismOfAction |
reduces amyloid plaques in the brain
|
| gptkbp:regulates |
under review (as of 2024)
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
gptkb:amyloid-related_imaging_abnormalities_(ARIA)
infusion-related reactions |
| gptkbp:target |
gptkb:amyloid_beta_protein
|
| gptkbp:targetEpitope |
N-terminal pyroglutamate amyloid-beta
|
| gptkbp:UNII |
1XU8F8V3Q1
|
| gptkbp:bfsParent |
gptkb:礼来
|
| gptkbp:bfsLayer |
5
|